Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02055066 | A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer. | PHASE1 | COMPLETED | 24 | — | — | Jan 1, 2014 | Mar 1, 2017 | Apr 21, 2017 | 2 | Belgium |
Number of patients with grade 3 or 4 toxicity
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | ARGX-111 0.3 mg/kg |
| Arm 2 | EXPERIMENTAL | ARGX-111 1.0 mg/kg |
| Arm 3 | EXPERIMENTAL | ARGX-111 3.0 mg/kg |
| Arm 4 | EXPERIMENTAL | ARGX-111 10 mg/kg |
| Name | Type | Description |
|---|---|---|
| ARGX-111 | DRUG | - |
Inclusion Criteria: 1. Written informed consent. 2. Age ≥ 18 years. 3. Performance status of 0 or 1. 4. Histological diagnosis of malignancy. 5. Cancer relapsing after, or refractory to standard therapy. 6. Malignancy over-expressing the c Met protein. 7. Presence of circulating tumor cells (CTCs)....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |